A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT ID: NCT03924947

Last Updated: 2023-09-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-10-23
• Study Completion Date: 2022-07-11

Brief Summary

Part 1 is a study to demonstrate that Creon (pancrelipase) delayed release (DR) capsules manufactured with a modernized process (MP) is non-inferior to currently marketed pancrelipase DR capsules in participants with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), as measured by coefficient of fat absorption (CFA). Part 2 is a study to demonstrate that Creon (pancrelipase) manufactured with an alternate active pharmaceutical ingredient site (AAPIS) is non-inferior to currently marketed active control (Creon®) in participants with EPI due to CF, as measured by CFA. Safety is evaluated in each part.

Conditions

Cystic Fibrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Part 1 Double-Blind Creon MP / Creon

After receiving open-label currently marketed Creon delayed release (Creon DR) capsules during a pre-randomization period, participants receive double-blind Creon DR capsules manufactured by modernized process pellets (Creon MP) in treatment period 1, followed by double-blind Creon DR capsules in treatment period 2. Participants also receive open-label currently marketed Creon DR for an interval of up to 28 days between periods 1 and 2, and during a 30-day follow-up period after period 2.

Group Type: EXPERIMENTAL

Pancrelipase

Intervention Type: DRUG

Delayed release capsules

Part 1 Double-Blind Creon / Creon MP

After receiving open-label currently marketed Creon DR capsules during a pre-randomization period, participants receive double-blind Creon DR capsules in treatment period 1, followed by double-blind Creon MP in treatment period 2. Participants also receive open-label currently marketed Creon DR for an interval of up to 28 days between periods 1 and 2, and during a 30-day follow-up period after period 2.

Group Type: EXPERIMENTAL

Pancrelipase

Intervention Type: DRUG

Delayed release capsules

Part 2 Double-Blind Creon AAPIS / Creon

After receiving open-label currently marketed Creon DR capsules during a pre-randomization period, participants receive double-blind Creon DR capsules manufactured at an alternate active pharmaceutical ingredient site (Creon AAPIS) in treatment period 1, followed by double-blind Creon DR capsules in treatment period 2. Participants also receive open-label currently marketed Creon DR for an interval of up to 28 days between periods 1 and 2, and during a 30-day follow-up period after period 2.

Group Type: EXPERIMENTAL

Pancrelipase

Intervention Type: DRUG

Delayed release capsules

Part 2 Double-Blind Creon / Creon AAPIS

After receiving open-label currently marketed Creon DR capsules during a pre-randomization period, participants receive double-blind Creon DR capsules in treatment period 1, followed by double-blind Creon AAPIS in treatment period 2. Participants also receive open-label currently marketed Creon DR for an interval of up to 28 days between periods 1 and 2, and during a 30-day follow-up period after period 2.

Group Type: EXPERIMENTAL

Pancrelipase

Intervention Type: DRUG

Delayed release capsules

Interventions

Pancrelipase

Delayed release capsules

Intervention Type: DRUG

Pancrelipase

Delayed release capsules

Intervention Type: DRUG

Other Intervention Names

Creon; ABT-SLV-245; Creon MP; Creon; ABT-SLV-245; Creon AAPIS

Eligibility Criteria

Inclusion Criteria

• Participant has a documented diagnosis of Cystic Fibrosis (CF) confirmed by:

• a sweat chloride test >= 60 mmol/L, and/or
• documented CF-causing cystic fibrosis transmembrane conductance regulator (CFTR) mutations and clinical features of CF.
• Participant has diagnosis of moderate to severe Exocrine Pancreatic Insufficiency (EPI), as determined by Fecal Elastase 1 (FE-1) < 15 μg/g at screening.
• Participant has EPI that is currently clinically controlled (no clinically overt steatorrhea or diarrhea) under treatment with a commercially available Pancreatic Enzyme Replacement Therapy (PERT), on an individually established dose regimen for more than 3 months prior to Screening, with a daily dose not exceeding 4,000 Lipase Units (LU)/g fat/day or 10,000 LU/kg/day.
• Participant is available for two (if participating in one of the parts) or four (if participating in both parts) hospitalization/confinement periods of 6 to 8 days each during the expected study window.
• Participant is able to consume a diet with 100 g fat/day, a minimum of 1 g/kg of protein/day and normal to low fiber content.

Exclusion Criteria

• BMI percentile for age less than 10% in participants less than 18 years of age.
• Participant has a history of any of the following gastrointestinal disorders (acute pancreatitis within 6 months prior to Visit 2, chronic pancreatitis, fibrosing colonopathy, distal intestinal obstruction syndrome (DIOS) within 6 months prior to Visit 2, C. difficile infection within 6 months prior to Visit 2, celiac disease, gastric bypass or partial/total gastrectomy, Crohn's disease or other inflammatory bowel disease, small bowel surgery (other than minor resection due to meconium ileus without resultant malabsorption syndrome), or any type of malignancy involving the digestive tract in the last 5 years).
• Participant has a history of any clinically significant endocrine, respiratory (except mild asthma or CF related lung disease), neurological, cardiac, renal, hepatic (including Hepatitis B or C), hematologic or psychiatric disease or disorder, or any other uncontrolled medical illness which might limit participation in or completion of the study.
• Participant requires concomitant treatment with any medication not allowed by the protocol or a prohibited medication is expected to be needed during the study.
• Participant is currently receiving nutritional supplementation via tube feeding (nasogastric, gastrostomy, jejunostomy).
• Participant has clinically significant (as per Investigator's judgment) abnormalities in clinical chemistry, hematology, or urinalysis (excluding findings that are associated with CF) such as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels >= 3 times the upper limit of normal values, or clinically significant (investigator opinion) elevation of uric acid.

• Minimum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AbbVie

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

University of Southern California /ID# 164571

Los Angeles, California, United States

Landon Pediatric Foundation /ID# 215411

Ventura, California, United States

Nemours Children's Health System /ID# 164553

Jacksonville, Florida, United States

Central FL Pulmonary Orlando /ID# 164558

Orlando, Florida, United States

The Cystic Fibrosis Institute /ID# 210757

Northfield, Illinois, United States

University of Iowa Hospitals and Clinics /ID# 164551

Iowa City, Iowa, United States

Via Christi Research /ID# 214266

Wichita, Kansas, United States

UH Cleveland Medical Center /ID# 206095

Cleveland, Ohio, United States

Cleveland Clinic Main Campus /ID# 212853

Cleveland, Ohio, United States

Nationwide Children's Hospital /ID# 225628

Columbus, Ohio, United States

Children's Hospital of Philadelphia - Main /ID# 208114

Philadelphia, Pennsylvania, United States

Vanderbilt University Medical Center /ID# 213434

Nashville, Tennessee, United States

Virginia Commonwealth University Medical Center Main Hospital /ID# 164574

Richmond, Virginia, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

http://www.rxabbvie.com/

Related Info

Other Identifiers

2017-000578-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

M16-111

Identifier Type: -

Identifier Source: org_study_id